Triple threat before surgery: could a new combo wipe out stomach cancer cells?
Disease control
Completed
This study tests whether giving a three-part treatment before surgery can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. The treatment combines an immunotherapy drug (tislelizumab) with standard chemotherapy and a short course of ra…
Phase: PHASE2 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC